Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage

[1] Dalsgaard S(2013)Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study J Child Adolesc Psychopharmacol 23 432-439

[2] Nielsen HS(1974)Metabolism and disposition of methylphenidate-14C: studies in man and animals J Pharmacol Exp Therapeut 191 535-547

[3] Simonsen M(2009)Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD Neuropharmacology 57 731-733

[4] Faraj BA(2012)Enantioselective determination of methylphenidate and ritalinic acid in whole blood from forensic cases using automated solid-phase extraction and liquid chromatography-tandem mass spectrometry J Anal Toxicol 36 560-568

[5] Israili ZH(1981)Synthesis and pharmacology of hydroxylated metabolites of methylphenidate J Med Chem 24 1237-1240

[6] Perel JM(2000)Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability Pharm Res 17 381-384

[7] Jenkins ML(1999)Pharmacokinetics and clinical effectiveness of methylphenidate Clin Pharmacokinet 37 457-470

[8] Holtzman SG(2006)Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline Eur Child Adolesc Psychiatry 15 476-495

[9] Cucinell SA(2010)Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation J Child Adolesc Psychopharmacol 20 49-54

[10] Nemoda Z(2013)Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate Expert Opin Drug Metab Toxicol 9 1001-1014

[1] Dalsgaard S(2013)Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study J Child Adolesc Psychopharmacol 23 432-439

[2] Nielsen HS(1974)Metabolism and disposition of methylphenidate-14C: studies in man and animals J Pharmacol Exp Therapeut 191 535-547

[3] Simonsen M(2009)Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD Neuropharmacology 57 731-733

[4] Faraj BA(2012)Enantioselective determination of methylphenidate and ritalinic acid in whole blood from forensic cases using automated solid-phase extraction and liquid chromatography-tandem mass spectrometry J Anal Toxicol 36 560-568

[5] Israili ZH(1981)Synthesis and pharmacology of hydroxylated metabolites of methylphenidate J Med Chem 24 1237-1240

[6] Perel JM(2000)Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability Pharm Res 17 381-384

[7] Jenkins ML(1999)Pharmacokinetics and clinical effectiveness of methylphenidate Clin Pharmacokinet 37 457-470

[8] Holtzman SG(2006)Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline Eur Child Adolesc Psychiatry 15 476-495

[9] Cucinell SA(2010)Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation J Child Adolesc Psychopharmacol 20 49-54

[10] Nemoda Z(2013)Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate Expert Opin Drug Metab Toxicol 9 1001-1014